{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "S",
          "position": "2019"
        },
        "variant_string_id": "LRRK2 G2019S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in the LRRK2 gene cause late-onset Parkinson's disease (PD). The G2019S mutation, located in the kinase domain, is reported to moderately enhance (2-3 fold) the autophosphorylation of LRRK2 and its ability to phosphorylate MBP, suggesting that over-activation of LRRK2 predisposes humans to develop PD.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly links LRRK2 mutations, specifically G2019S, to PD through increased kinase activity, which is hypothesized to contribute to disease pathogenesis by over-activation of the protein."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study utilized autophosphorylation and phosphorylation of MBP, moesin, ezrin, radixin, and a peptide substrate (LRRKtide) to assess LRRK2 kinase activity. These assays reflect the kinase function of LRRK2, which is implicated in PD pathogenesis.",
          "judgment": "Yes",
          "reasoning": "The general class of kinase activity assays (autophosphorylation and substrate phosphorylation) used in the paper effectively models the proposed disease mechanism of increased kinase activity leading to PD.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "The paper includes kinase-inactive LRRK2 (D2017A) as a negative control and wild-type LRRK2 as a normal control. Assays were performed in triplicate as indicated in the results for LRRKtide phosphorylation (mean specific activity Â± S.D. for assays carried out in triplicate).",
          "judgment": "Yes",
          "reasoning": "Both normal (wild-type LRRK2) and abnormal (kinase-inactive D2017A) controls are used, and replicates are explicitly mentioned (triplicate assays), meeting the criteria for basic controls and replicates.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "The study compares the activity of nine PD mutations, including G2019S, against wild-type LRRK2 and kinase-inactive LRRK2 (D2017A). However, no specific known pathogenic or benign variants are explicitly classified as controls with independent P/LP or B/LB criteria outside of PS3/BS3.",
          "judgment": "No",
          "reasoning": "While multiple variants are tested, the paper does not specify variant controls as known pathogenic or benign with classifications independent of PS3/BS3 evidence. The comparisons are primarily against wild-type and kinase-inactive forms, not against established variant controls.",
          "next_step_or_outcome": "Max PS3_supporting / Max BS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The functional evidence for LRRK2 G2019S supports a pathogenic role with a strength of PS3_supporting. This is based on the clear definition of disease mechanism (increased kinase activity linked to PD), applicability of kinase activity assays, presence of basic controls and replicates, but lack of specific variant controls with independent classification, limiting the strength to supporting."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "H",
          "position": "1941"
        },
        "variant_string_id": "LRRK2 R1941H"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in the LRRK2 gene cause late-onset Parkinson's disease (PD). The paper indicates that not all mutations increase kinase activity, with R1941H showing nearly inactive kinase activity compared to wild-type LRRK2.",
          "judgment": "Yes",
          "reasoning": "The paper defines the disease mechanism for LRRK2 mutations in PD, though the specific effect of R1941H (decreased activity) contrasts with the typical hypothesis of over-activation. The mechanism is still linked to altered kinase function."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study utilized autophosphorylation and phosphorylation of MBP, moesin, and LRRKtide to assess LRRK2 kinase activity. These assays reflect the kinase function of LRRK2, which is implicated in PD pathogenesis.",
          "judgment": "Yes",
          "reasoning": "The kinase activity assays used are applicable to model the disease mechanism of altered kinase function in PD, even if the effect is a decrease in activity for this variant.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "The paper includes kinase-inactive LRRK2 (D2017A) as a negative control and wild-type LRRK2 as a normal control. Assays were performed in triplicate as indicated in the results for LRRKtide phosphorylation.",
          "judgment": "Yes",
          "reasoning": "Both normal and abnormal controls are used, and replicates are explicitly mentioned, meeting the criteria for basic controls and replicates.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "The study compares the activity of nine PD mutations, including R1941H, against wild-type LRRK2 and kinase-inactive LRRK2 (D2017A). No specific known pathogenic or benign variants are classified as controls with independent P/LP or B/LB criteria.",
          "judgment": "No",
          "reasoning": "The paper lacks variant controls with independent classifications outside of PS3/BS3 evidence, limiting the strength of the evidence.",
          "next_step_or_outcome": "Max PS3_supporting / Max BS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The functional evidence for LRRK2 R1941H supports a pathogenic role with a strength of PS3_supporting. Despite the decrease in kinase activity, the disease mechanism is defined, assays are applicable, and basic controls/replicates are present, but the lack of specific variant controls limits the strength to supporting."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "I",
          "alt": "T",
          "position": "2012"
        },
        "variant_string_id": "LRRK2 I2012T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in the LRRK2 gene cause late-onset Parkinson's disease (PD). The paper indicates that I2012T shows nearly inactive kinase activity compared to wild-type LRRK2.",
          "judgment": "Yes",
          "reasoning": "The disease mechanism for LRRK2 mutations in PD is defined, with altered kinase function (decrease in activity for I2012T) linked to pathogenesis."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study utilized autophosphorylation and phosphorylation of MBP, moesin, and LRRKtide to assess LRRK2 kinase activity.",
          "judgment": "Yes",
          "reasoning": "The kinase activity assays are applicable to model altered kinase function in PD, relevant even for decreased activity.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "The paper includes kinase-inactive LRRK2 (D2017A) and wild-type LRRK2 as controls. Assays were performed in triplicate.",
          "judgment": "Yes",
          "reasoning": "Criteria for basic controls and replicates are met with both types of controls and triplicate assays.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "The study compares nine PD mutations, including I2012T, against wild-type and kinase-inactive LRRK2, but lacks specific variant controls with independent classifications.",
          "judgment": "No",
          "reasoning": "No variant controls with independent P/LP or B/LB criteria are specified, limiting evidence strength.",
          "next_step_or_outcome": "Max PS3_supporting / Max BS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The functional evidence for LRRK2 I2012T supports a pathogenic role with a strength of PS3_supporting, based on defined disease mechanism, applicable assays, and basic controls/replicates, but limited by the absence of specific variant controls."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "I",
          "alt": "T",
          "position": "2020"
        },
        "variant_string_id": "LRRK2 I2020T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in the LRRK2 gene cause late-onset PD. I2020T possesses significantly less kinase activity than wild-type LRRK2.",
          "judgment": "Yes",
          "reasoning": "The disease mechanism is defined with altered kinase function linked to PD, even though I2020T shows decreased activity."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Kinase activity assessed via autophosphorylation and phosphorylation of MBP, moesin, and LRRKtide.",
          "judgment": "Yes",
          "reasoning": "Assays are applicable to model kinase function alterations in PD.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Controls include kinase-inactive LRRK2 (D2017A) and wild-type LRRK2. Assays in triplicate.",
          "judgment": "Yes",
          "reasoning": "Basic controls and replicates criteria are met.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "Nine PD mutations compared, but no specific variant controls with independent classifications.",
          "judgment": "No",
          "reasoning": "Lack of variant controls with independent P/LP or B/LB criteria limits evidence strength.",
          "next_step_or_outcome": "Max PS3_supporting / Max BS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The functional evidence for LRRK2 I2020T supports a pathogenic role with a strength of PS3_supporting, due to defined mechanism, applicable assays, and controls/replicates, but limited by absence of specific variant controls."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "R",
          "position": "2385"
        },
        "variant_string_id": "LRRK2 G2385R"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in LRRK2 cause late-onset PD. G2385R possesses very low catalytic activity in all assays.",
          "judgment": "Yes",
          "reasoning": "Disease mechanism is defined with altered kinase function linked to PD, despite decreased activity for G2385R."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Kinase activity assessed via autophosphorylation and phosphorylation of substrates like MBP and LRRKtide.",
          "judgment": "Yes",
          "reasoning": "Assays are applicable to model kinase function changes in PD.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Controls include kinase-inactive and wild-type LRRK2. Assays in triplicate.",
          "judgment": "Yes",
          "reasoning": "Criteria for controls and replicates are met.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "Nine PD mutations compared, but no specific variant controls with independent classifications.",
          "judgment": "No",
          "reasoning": "Lack of variant controls with independent criteria limits evidence strength.",
          "next_step_or_outcome": "Max PS3_supporting / Max BS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The functional evidence for LRRK2 G2385R supports a pathogenic role with a strength of PS3_supporting, based on defined mechanism and applicable assays with controls/replicates, but limited by absence of specific variant controls."
    }
  ]
}